Category: Uncategorized

Noble Capital Markets Research Report Thursday, July 10, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Strong Start to Fiscal Year 2026
Eledon Pharmaceuticals (ELDN)/OUTPERFORM – Meeting Highlights Tegoprubart Data Milestones and New Indications

AZZ (AZZ/$100.73 | Price Target: $112)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Strong Start to Fiscal Year 2026
Rating: OUTPERFORM

FY 2026 first quarter financial results. AZZ reported adjusted net income of $53.8 million or $1.78 per share compared to $44.0 million or $1.46 per share during the prior year period. We had forecast adjusted net income of $50.1 million or $1.66 per share. Compared to the first quarter of FY 2025, sales increased 2.1% to $422.0 million. Adjusted EBITDA increased 13.1% to $106.4 million, representing 25.2% of sales compared to 22.8% of sales during the prior year period. We had projected adjusted EBITDA of $99.5 million. 

Meaningful debt reduction. Cash from operations during the fiscal first quarter amounted to $314.8 million, including proceeds of $273.2 million received from AVAIL’s sale of the Electrical Products Group. Following debt reduction of $285.4 million, AZZ ended the quarter with a net leverage ratio of 1.7x TTM adjusted EBITDA. As of May 31, long-term debt, gross was $614.9 million compared to $900.3 million on February 28. Net of unamortized debt issuance costs, long-term debt was $569.8 million on May 31 compared to $852.4 million on February 28.

Get the Full Report

Eledon Pharmaceuticals (ELDN/$3.4 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Meeting Highlights Tegoprubart Data Milestones and New Indications
Rating: OUTPERFORM

R&D Day Highlighted Science, Current Trials, Future Indications. We attended the Eledon R&D Day on July 9 to hear and evaluate the progress in tegoprubart development. The presentations focused on the current clinical indications in renal transplantation, islet cell transplantation, xenotransplants, and plans for liver and other solid organ transplants. Conference presentation dates for upcoming data announcements were also announced.

Phase 1b Data Update Is Planned For August. The Phase 1b open-label trial has been expanded to enroll up to 36 patients, an increase from the original 9 patients. Data is scheduled for presentation at the World Transplant Congress on August 9, 2025. Previous data presentations have included 13 patients. We expect to see follow-up data from more patients treated longer, with data from additional patients beyond the initial 12-month trial duration.

Get the Full Report

Noble Capital Markets Research Report Tuesday, July 8, 2025

Companies contained in today’s report:

Alliance Resource Partners (ARLP)/OUTPERFORM – Outlook Remains Favorable, Increasing 2025 Estimates
E.W. Scripps (SSP)/OUTPERFORM – Strengthening Its Station Portfolio
Xcel Brands (XELB)/OUTPERFORM – Seeking Fuel For Growth

Alliance Resource Partners (ARLP/$26.72 | Price Target: $31)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Outlook Remains Favorable, Increasing 2025 Estimates
Rating: OUTPERFORM

Updating estimates. We are increasing our 2025 adjusted EBITDA and EPU estimates to $676.5 million and $2.55, respectively, from $672.6 million and $2.52. We increased our crude oil and natural gas price estimates based on CME futures settlements, which had a positive impact on oil and gas royalty revenue. Our 2026 adjusted EBITDA and EPS estimates are unchanged at $678.3 million and $2.60, respectively. While management expects the average coal sales price per ton to trend lower in 2026 due to higher-priced contracts rolling off, we think 2025 longwall moves and actions to improve productivity and cost effectiveness could help offset the impact of lower prices.

Recent legislation expected to benefit the fossil fuel industry. Following several executive orders earlier in the year intended to support the coal industry and delay coal power plant retirements, the Big Beautiful Bill (BBB) was signed into law on July 4 and is expected to benefit the fossil fuel industry. Among other things, the BBB phases out many of the clean energy tax credits established under the Inflation Reduction Act and creates a supportive environment for oil, gas, and coal production.

Get the Full Report

E.W. Scripps (SSP/$3.42 | Price Target: $10)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Strengthening Its Station Portfolio
Rating: OUTPERFORM

Compelling station swap. Scripps will be selling its stations in Lansing MI and Lafayette LA to Gray Television (GTN: Not Rated) and buying stations in Colorado Springs, CO and Grand Junction, CO and a station in Twin Falls ID. We view the move favorably, given that Scripps will create station duopolies and strengthen its presence in the West. We believe that the move will create significant efficiencies for both companies, eliminating back office, duplicative, and overhead costs. This will be an even swap with no cash compensation to either party. 

FCC fast track? The FCC has signaled its willingness to fast track the regulatory process, likely to provide a “waiver” to create duopolies rather than to seek a longer review/rulemaking process. As such, we believe that the transaction could be completed by year end. 

Get the Full Report

Xcel Brands (XELB/$1.58 | Price Target: $9)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Seeking Fuel For Growth
Rating: OUTPERFORM

Files S1. The company plans to sell 1.381 million shares on a “best efforts” basis and pre-funded warrants. Pre-funded warrants are exercisable at any time after the date of issuance and may be exercised at any time. Notably, management has indicated its interest in participating in the offering for up to 10% of the shares. Following the prospective sale, total shares outstanding would increase to 3.819 million shares. 

Use of proceeds. Based on the current stock price and assuming all shares are sold, management expects to generate roughly $1.9 million in net proceeds from the offering. The company plans to use the proceeds for working capital and general corporate purposes and toward a $50,000 principal loan payment to a company controlled by Robert D’Loren, the company’s Chairman and CEO. 

Get the Full Report

Noble Capital Markets Research Report Thursday, July 3, 2025

Companies contained in today’s report:

Commercial Vehicle Group (CVGI)/OUTPERFORM – A Debt Refi
Government Solutions (Government Solutions) – CoreCivic and GEO poised to Benefit From Big Beautiful Bill
MariMed Inc (MRMD)/OUTPERFORM – Rec Sales to Begin in Delaware
ONE Group Hospitality (STKS)/OUTPERFORM – Diners Seeking “Uniqueness and Entertainment”

Commercial Vehicle Group (CVGI/$2 | Price Target: $4)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Debt Refi
Rating: OUTPERFORM

Refi. Commercial Vehicle Group successfully refinanced its debt, extending the maturity out to 2030 from 2027. We believe this should provide the Company with additional financial flexibility as management continues to drive further operational efficiency.

Details. The Company went from an $85 million term loan to a $95 million term loan and from a $125 million ABL to a $115 million ABL. Proceeds were used to repay $120.1 million outstanding under the previous facility. The initial interest rate on the term loan is 9.75%, although future rates will have a tiered interest cost based on the consolidated leverage ratio. The initial ABL rate is SOFR plus 1.75%.

Get the Full Report

Government Solutions
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
CoreCivic and GEO poised to Benefit From Big Beautiful Bill

Big Beautiful Bill. The Senate version of the “One Big Beautiful Bill Act” aligns with or even improves upon the House version when it comes to spending on immigration. While it remains to be seen the exact version that will come out of the reconciliation process and be sent to President Trump for his signature, the proposed versions should prove to be beneficial to both CoreCivic and The GEO Group.

Detention Budget. Both the Senate and House proposals call for $45 billion of funding for detention capacity or an additional $10.6 billion annually through fiscal 2029. This would represent an over 300% increase over the current detention budget. This level of funding could support detention bed capacity in excess of 115,000 beds, up from a current 41,500.

Get the Full Report

MariMed Inc (MRMD/$0.08 | Price Target: $0.25)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Rec Sales to Begin in Delaware
Rating: OUTPERFORM

Recreational Cannabis. After legislation approving recreational cannabis in April 2023, Delaware will finally commence sales of recreational cannabis on August 1st of this year. Legal recreational cannabis can be purchased in the 13 existing medical dispensaries as well as through the 30 recreational licenses the state has approved. We expect sales to be derived not only from the state population, many of whom currently travel to existing legal states such as Maryland and New Jersey to obtain the product, but also from the estimated 30 million tourists that visit the state annually.

Delaware Market. Delaware has had a medical market for a while. The market is estimated to be approximately $50 million in size, with flattish growth to 2029 when the medical is projected to rise to $55 million. The recreational cannabis market could grow to the $250-$300 million level, according to various government projections.

Get the Full Report

ONE Group Hospitality (STKS/$4.75 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Diners Seeking “Uniqueness and Entertainment”
Rating: OUTPERFORM

Diner Views. Today’s diners are seeking out venues that prioritize entertainment and uniqueness, according to a Yelp survey that analyzed consumer web searches from January to March. The Yelp findings are in-line with recent research by hospitality management platform SevenRooms. According to SevenRooms’ 2025 U.S. Restaurant Industry Trends, consumers who dine out value unique experiences, even at a premium, with 74% of consumers returning to a restaurant after a unique experience.

A Vibe Dining Leader. As a leader in Vibe Dining, ONE Hospitality is well positioned to capitalize on this trend through its portfolio of concepts, including chains STK, Benihana, Kona Grill, and RA Sushi, as well as the Salt Water Social and Samurai concepts. These upscale and polished casual, high-energy restaurants and lounges provide entertainment and unique experiences for diners, as well as one-of-a-kind, celebratory experiences that bring customers back.

Get the Full Report

Noble Capital Markets Research Report Wednesday, July 2, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – AZZ Acquires Canton Galvanizing, LLC
GoHealth (GOCO)/OUTPERFORM – Credit Amendment Provides Reprieve
Resources Connection (RGP)/OUTPERFORM – A Cooperation Agreement and New Directors
The GEO Group (GEO)/OUTPERFORM – From Lease to Ownership

AZZ (AZZ/$96.74 | Price Target: $112)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
AZZ Acquires Canton Galvanizing, LLC
Rating: OUTPERFORM

Bolt-on acquisition. AZZ Inc. entered into an agreement to acquire all the assets of Canton Galvanizing, LLC, a privately held hot dip galvanizing company based in Canton, Ohio. While the terms of the transaction were not disclosed, AZZ expects the transaction to be accretive to earnings within the first year of operation. Founded in 2019, Canton provides hot-dip galvanizing to customers in the U.S. Midwest and specializes in coating small to mid-size parts.

Strengthens AZZ’s presence in the U.S. Midwest. The strategic acquisition expands AZZ’s Metal Coatings capabilities in the US. Midwest and increases its total galvanizing network to 42 sites in North America. It has been renamed AZZ Galvanizing – Canton East LLC. With a spinning operation and a 21-foot kettle, Canton is known for quick turnaround times and excellent customer service.

Get the Full Report

GoHealth (GOCO/$5.92 | Price Target: $25)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Credit Amendment Provides Reprieve
Rating: OUTPERFORM

Amended credit agreement. On June 30, the company announced an amendment to its credit agreement, extending the maturity of the company’s Class A Revolving Commitments from Q2 end to Q3 end. Moreover, any interest due on the revolver and refinanced term loans through that date will be paid in-kind. The amendment also waived financial covenant testing for Q2 and Q3, offering the company a temporary liquidity reprieve.

Cost of amendment. As part of the amendment, GoHealth will pay a 1.00% amendment fee to consenting lenders, which, along with all interest through September 30, will be paid in-kind and added to the principal balance of its loans. As a result, we estimate these provisions will increase the company’s outstanding debt by approximately $6 million.

Get the Full Report

Resources Connection (RGP/$5.76 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Jacob Mutchler jmutchler@noblefcm.com |
A Cooperation Agreement and New Directors
Rating: OUTPERFORM

Cooperation Agreement. Resources Connection has entered into a “Cooperation Agreement” with shareholder Circumference Group LLC. According to a Form 3 filing of June 30th, Circumference owns 1,289,243 RGP shares, representing 3.9% of the common shares outstanding as of March 31st.

Board Changes. As part of the Cooperation Agreement, RGP appointed Jeff Fox, founding partner and CEO of Circumference Group, and Filip Gyde, former CEO of Computer Task Group, to the Board. Current Board members Anthony Cherbak and Neil Dimick will retire from the Board following the conclusion of their terms in October 2025.

Get the Full Report

The GEO Group (GEO/$24.49 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
From Lease to Ownership
Rating: OUTPERFORM

A Purchase. The GEO Group is purchasing the currently leased 770-bed Western Region Detention facility for $60 million, or $77,900/bed. GEO is currently leasing the facility at a cost of $5.1 million annually. GEO has had a long-term contract with the U.S. Marshals Service for use of the facility, which generates approximately $57 million of annualized revenue.

A Tax Savings. Expected to close by the end of July, the transaction is expected to be funded as a like kind real estate property exchange with proceeds from the previously announced sale of the GEO-owned  Lawton Correctional Facility, which is expected to close on July 25th, resulting in an estimated capital gains cash tax savings of approximately $9.5 million.

Get the Full Report

Noble Capital Markets Research Report Tuesday, July 1, 2025

Companies contained in today’s report:

Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Some Award Updates
Kratos Defense & Security (KTOS)/OUTPERFORM – Completes $575 Million Capital Raise
Unicycive Therapeutics (UNCY)/OUTPERFORM – CRL Letter Received As Second Manufacturer Generates Data

Great Lakes Dredge & Dock (GLDD/$12.19 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some Award Updates
Rating: OUTPERFORM

Awards. Yesterday, Great Lakes provided an update on some recent awards. Each of the awards adds to the Company’s significant backlog, which stood at approximately $1 billion with an additional $265 million in low bids and options pending award at the end of the first quarter. The large backlog, with a majority being higher margin capital projects, provides strong visibility for 2025 and into 2026.

Woodside LNG. The Company received Notice to Proceed from Bechtel Energy for dredging work on the Woodside Louisiana LNG project. The first phase of work, which was awarded in the second quarter of 2025, includes the construction of a ship berthing basin for use by large LNG carriers, with potential for award of two options to expand the scope of construction for additional ship berths. Dredging operations are expected to commence in early 2026.

Get the Full Report

Kratos Defense & Security (KTOS/$46.45 | Price Target: $44)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Completes $575 Million Capital Raise
Rating: OUTPERFORM

Capital Raise. Kratos completed its previously announced offering of Kratos common stock, raising  $575 million in gross proceeds, at a public offering price of  $38.50 per share, for a total of 14,935,065 shares of common stock, which includes the exercise of the underwriter’s option to purchase additional shares. Net proceeds from the offering were approximately  $556 million. Noble Capital participated as a co-manager of the offering.

Use of Proceeds. Kratos expects to use the net proceeds of the offering to (i) fund investments and capital expenditures to scale and successfully execute on large, mission critical National Security priorities related to existing programs, recent program awards and significant high-probability pipeline opportunities; (ii) to finance important customer and program targeted acquisitions; (iii) and for general corporate purposes.

Get the Full Report

Unicycive Therapeutics (UNCY/$4.77 | Price Target: $60)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
CRL Letter Received As Second Manufacturer Generates Data
Rating: OUTPERFORM

Approval Delay Is Not A Surprise. Unicycive announced that it has received a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). This was expected following the announcement earlier this month stating that the FDA manufacturing inspection had found deficiencies with one of the OLC contract manufacturers. The company has switched to one of its other manufacturers, which we believe can resolve the issues quickly. We see approval possible around 4Q25 to 1Q26.

Plans To Address The Issues. Unicycive plans to hold a Type A meeting with the FDA to determine its requirements for resolution of the issues cited in the CRL. The company’s second manufacturer already produces OLC and has been generating data for FDA certification. This should allow Unicycive to submit any additional data requested quickly to resolve the issue.

Get the Full Report

Noble Capital Markets Research Report Monday, June 30, 2025

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Promising New Data Highlights the Potential for a Significant Copper Discovery

Aurania Resources (AUIAF/$0.17 | Price Target: $0.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Promising New Data Highlights the Potential for a Significant Copper Discovery
Rating: OUTPERFORM

Application of two-dimensional inversion technology. Aurania Resources announced that six highly conductive anomalies have been revealed at the company’s Awacha porphyry copper target based on reprocessed data from a 2021 mobile magnetotellurics (MobileMT) survey using the latest two-dimensional (2D) inversion technology. Compared to the previously employed 1D algorithm, the 2.5D code accounts for the actual topography of the area, resulting in more accurate mapping of subsurface conductivity.

Six promising anomalies at Awacha. New inversion data has confirmed the presence of six high-conductivity anomalies that begin 250 meters from the surface and exhibit deep roots. The anomalies are of significant interest because zones of elevated conductivity often correlate with porphyry copper deposits due to the presence of conductive sulphide minerals and porphyry-related alteration.

Get the Full Report

Noble Capital Markets Research Report Friday, June 27, 2025

Companies contained in today’s report:

AZZ (AZZ)/OUTPERFORM – Quarterly Cash Dividend Increased by 17.6%, 1Q FY2026 Financial Results to be Released on July 9
Bit Digital (BTBT)/OUTPERFORM – A Flurry of News
Steelcase (SCS)/OUTPERFORM – Post Call Commentary
V2X (VVX)/OUTPERFORM – An $118 Million Contract

AZZ (AZZ/$92.75 | Price Target: $112)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Quarterly Cash Dividend Increased by 17.6%, 1Q FY2026 Financial Results to be Released on July 9
Rating: OUTPERFORM

Increase in the quarterly cash dividend. AZZ announced a 17.6% increase in the quarterly cash dividend to $0.20 per share, or $0.80 on an annualized basis, from $0.17 per share, or $0.68 on an annualized basis. The dividend is payable on July 31 to shareholders of record as of the close of business on July 10. In our view, the dividend increase reflects management’s confidence in the company’s near- and long-term outlook.

First Quarter FY 2026 financial results. AZZ will release its first quarter financial results after the market close on Wednesday, July 9. Management will host an investor conference call and webcast on Thursday, July 10, at 11:00 am ET. We look forward to an update regarding the company’s new aluminum coil coating facility in Washington, Missouri, that is ramping up production, along with a review of market fundamentals and the company’s capital allocation priorities.

Get the Full Report

Bit Digital (BTBT/$1.99 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Flurry of News
Rating: OUTPERFORM

News. Bit Digital released a flurry of news over the past two days, including a strategic shift in its business strategy, the potential IPO of its WhiteFiber subsidiary, and a $150 million equity offering. Needless to say, a lot to digest. If completed, the announced shifts would result in a significant change to Bit Digital.

Ethereum Focus. Operationally, Bit Digital will exit the bitcoin mining business and transition to become a pure-play Ethereum staking and treasury company. Given the economics of bitcoin mining versus Ethereum staking, we see the rationale in the move. The Company has commenced a strategic alternatives process for the Bitcoin mining operations.

Get the Full Report

Steelcase (SCS/$10.89 | Price Target: $16)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Post Call Commentary
Rating: OUTPERFORM

Mixed Environment. Steelcase continues to face a mixed environment, both on a vertical basis and a geographical basis. The key large corporate customer cohort is doing well, driven by a number of factors such as return to office, but education and government have been hit by funding uncertainties. Germany and France remain sluggish in the key small-to-mid-sized business, but India and China are doing better.

International Actions. Steelcase is taking steps to implement additional cost reduction efforts in Europe, given the weak macroeconomic factors and lower demand in France and Germany. A goal of these actions is to get the International segment back to profitability.

Get the Full Report

V2X (VVX/$48.47 | Price Target: $72)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
An $118 Million Contract
Rating: OUTPERFORM

Support Services. According to the daily Department of Defense contract announcements, V2X subsidiary Vectrus Systems has been awarded an $118 million cost-plus-fixed-fee undefinitized contract for base support services in support of the Iraq F-16 program. This is another in a long line of recent wins for V2X, demonstrating the V2X value proposition and confirming the significant traction on near-term Foreign Military and International opportunities previously highlighted by management.

Details. The contract provides for base operating support, base life support, and security services. Work will be performed at Martyr BG Ali Flaih Air Base, Iraq, and is expected to be completed by Nov. 30, 2026. This contract involves Foreign Military Sales (FMS) to Iraq. This contract was a sole source acquisition. FMS funds in the amount of $57.8 million are being obligated at the time of award.

Get the Full Report

Noble Capital Markets Research Report Thursday, June 26, 2025

Companies contained in today’s report:

Steelcase (SCS)/OUTPERFORM – First Look At A Solid First Quarter

Steelcase (SCS/$10.62 | Price Target: $16)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
First Look At A Solid First Quarter
Rating: OUTPERFORM

1Q26. Steelcase reported solid results for the first quarter of fiscal 2026. Revenue grew 7% y-o-y to $779 million, towards the upper end of guidance. We had forecast $760 million and the consensus was $762 million. Gross margin of 33.9% was up 170 bp y-o-y and above management’s 33% guide. Steelcase reported net income of $13.6 million, or EPS of $0.11, and adjusted EPS of $0.20, compared to $10.9 million, $0.09, and $0.16, respectively, last year. We were at adjusted EPS of $0.14, while consensus was $0.13.

Quarterly Drivers. The Americas business was up 9%, both on a reported and organic basis, driven by a higher beginning backlog compared to the prior year and included strong growth from large corporate, government, and healthcare customers. International was up 1% on a reported basis but down 1% on an organic basis, driven by declines in Germany and France, mostly offset by growth in India, the UK, and China.

Get the Full Report

Noble Capital Markets Research Report Wednesday, June 25, 2025

Companies contained in today’s report:

Comstock (LODE) /MARKET PERFORM –  Strategic Partnership with Virtus Renewables

Comstock (LODE/$3.55)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Strategic Partnership with Virtus Renewables
Rating: MARKET PERFORM

Strategic partnership with Virtus. Comstock Metals forged a strategic partnership with Virtus Renewables Service Group Inc. Comstock and Virtus will jointly develop and deliver comprehensive recycling, decommissioning, and logistics solutions designed to suit the specific needs of the renewable energy markets. The partnership enables a systemwide service offering with expanded industry reach to offer environmentally conscious solutions for renewable energy clients across the United States.

Mutual benefits. Virtus offers a comprehensive suite of operations, project management, and maintenance services for solar and battery storage projects. Combining Virtus’s end-to-end renewable energy service expertise with Comstock’s industry-leading, zero-landfill solution enhances its ability to serve the renewable energy market and benefit from a full lifecycle certification process that adheres to the highest standards of sustainability, reliability, and service. Comstock is the first solar panel recycling company in North America to be certified by Sustainable Electronics Recycling International (SERI) to the R2v3/RIOS Responsible Recycling Standard.

Get the Full Report

Noble Capital Markets Research Report Tuesday, June 24, 2025

Companies contained in today’s report:

Bit Digital (BTBT)/OUTPERFORM – New Credit Agreement
Bitcoin Depot (BTM)/OUTPERFORM – Potential Fuel for Growth
Ocugen (OCGN)/OUTPERFORM – Merger Agreement Moves NeoCart Into A New Company
QuoteMedia Inc. (QMCI)/OUTPERFORM – Raising Price Target On Favorable Outlook

Bit Digital (BTBT/$2.32 | Price Target: $5.5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Jacob Mutchler jmutchler@noblefcm.com |
New Credit Agreement
Rating: OUTPERFORM

Credit Agreement. Yesterday, Bit Digital’s WhiteFiber subsidiary announced a CAD$60 million credit facility with Royal Bank of Canada (RBC). We view this step favorably, as the facility not only provides funds to support the continued buildout of WhiteFiber’s Tier-3 AI data center portfolio but also is a confirmation of Bit Digital’s AI business model, in our view.

Terms. While we expect an 8-K to be filed with a full accounting of the terms, the credit agreement is among RBC and ENOVUM Data Centers Corp. and its Montreal II project as borrowers and guarantors, and is non-recourse to WhiteFiber or Bit Digital. It encompasses a real estate term loan, equipment financing, and a revolving facility. The facilities carry interest rates of CORRA plus 250 bps and a 3-year term.

Get the Full Report

Bitcoin Depot (BTM/$5.35 | Price Target: $9)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Potential Fuel for Growth
Rating: OUTPERFORM

Shelf registration. On June 20, the company filed a registration statement with the SEC for a $100 million mixed securities shelf registration, which could include Class A common stock, preferred shares, warrants, and units. The registration statement also included an at the money (ATM) sales agreement, which will allow the company to sell up to $50 million in class A common shares directly into the market.

Bolstering capital availability. We view the registration positively, as it provides the company with flexibility to raise capital opportunistically based on market conditions and the strength of BTM’s share price, which is up approximately 230% year-to-date. Importantly, this added capital access could support strategic initiatives such as tuck-in acquisitions or the purchase of additional kiosks, positioning the company to accelerate its network expansion and long-term revenue growth trajectory.

Get the Full Report

Ocugen (OCGN/$0.98 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Merger Agreement Moves NeoCart Into A New Company
Rating: OUTPERFORM

NeoCart Transferred To Form New Regenerative Medicine Company. Ocugen has announced that it has entered into a merger agreement with Carisma Therapeutics to form a new company. Ocugen will transfer its wholly-owned regenerative medicine division, OrthoCellix, including NeoCart, an autologous cartilage implant technology that uses a patient’s cells to repair articular cartilage defects in the knee. The all-stock transaction is valued at $150 million, with Ocugen shareholders owning 90% of the new company.

We Expect The New Company To Accelerate NeoCart Development. Ocugen has been refining the Phase 3 trial design and has planned to start Phase 3 trials during FY2025. NeoCart has received Regenerative Medicine Advanced Therapy (RMAT) designation, which accelerates BLA review and could lead to faster approval. While the NeoCart data has been strong, NeoCart was a legacy product that was acquired by Ocugen as part of its 2019 reverse merger with Histogenics. Regenerative medicine is outside Ocugen’s main focus, and we believe it can be developed more rapidly by a company focused on regenerative medicine.

Get the Full Report

QuoteMedia Inc. (QMCI/$0.16 | Price Target: $0.23)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Raising Price Target On Favorable Outlook
Rating: OUTPERFORM

Solid Q1 Results. The company reported solid Q1 results, with revenue growing 3% over the prior year period to $4.8 million, marking the highest quarterly revenue in the company’s history. Adj. EBITDA of $0.4 million in Q1 was moderately lower than our estimate of $0.5 million estimate. We believe its business pipeline appears to be improving and should gain momentum throughout the year and into 2026. 

Capitalizing less development costs. Notably, the company capitalized less development costs in Q1 than in prior quarters, leading to more development costs expensed in Q1. While this impacted Q1, we believe that margins should improve as the company begins to recognize the revenue from the new business “wins” in future quarters. Furthermore, the company will be expensing development costs at a similar rate to Q1 moving forward.

Get the Full Report

Noble Capital Markets Research Report Monday, June 23, 2025

Companies contained in today’s report:

Nicola Mining Inc. (HUSIF)/OUTPERFORM – Nicola Commences 2025 New Craigmont Exploration Drilling

Nicola Mining Inc. (HUSIF/$0.51 | Price Target: $0.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Nicola Commences 2025 New Craigmont Exploration Drilling
Rating: OUTPERFORM

New Craigmont drilling program. Nicola Mining (TSX.V: NIM, OTCQB: HUSIF) has commenced the 2025 exploration and diamond drilling program at its New Craigmont Copper Project, which will entail 4,000 to 5,000 meters of drilling. The program is expected to run from June through September and cost $1.5 million to $2.0 million. The purpose of the 2025 program is to collect geological data for target development for a potential porphyry copper system at New Craigmont.

Identifying targets using artificial intelligence. In collaboration with ALS Geoanalytics (formerly ALS GoldSpot), five priority targets, three of which are included in the 2025 program, were identified using artificial intelligence (AI)-based methods to analyze and correlate geophysical and geochemical data from Nicola’s exploration data. The collaboration harnesses the power of AI to identify high-potential targets which could increase the probability of successful outcomes.

Get the Full Report

Noble Capital Markets Research Report Friday, June 20, 2025

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – Strong Start to 2025
MAIA Biotechnology (MAIA)/OUTPERFORM – Roche Forms Agreement For THIO Combination Studies
Nutriband (NTRB)/OUTPERFORM – Manufacturing Milestone Allows Development To Move Forward As Expected

Euroseas (ESEA/$45.69 | Price Target: $53)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Strong Start to 2025
Rating: OUTPERFORM

First quarter 2025 financial results. Euroseas Ltd. reported adjusted EBITDA and earnings per share (EPS) of $37.1 million and $3.76, respectively, compared to $24.6 million and $2.66 during the prior year period. Revenue increased due to a higher average number of vessels compared to the same period last year, while operating expenses declined. We had projected adjusted EBITDA and EPS of $34.7 million and $3.35, respectively. Relative to our estimates, revenues were higher, based on an average daily time charter equivalent rate of $27,806, versus our estimate of $26,221, while operating expenses were lower. Vessel operating expenses totaled $12.3 million compared to our estimate of $13.3 million.

Market outlook. The containership sector may face some challenges, including the potential for transit to resume through the Suez Canal, weaker economic conditions due to fluid trade policies, and a high industry order book, which could increase the supply of vessels. However, the company’s strong charter coverage through 2026 could insulate it from the potential for lower rates. Moreover, the feeder and intermediate segments of the market have relatively low order books, and demand for vessels remains strong.

Get Full Report

MAIA Biotechnology (MAIA/$1.8 | Price Target: $14)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Roche Forms Agreement For THIO Combination Studies
Rating: OUTPERFORM

MAIA Makes Its Third Supply Agreement. MAIA announced that it has entered a supply agreement with Genentech/Roche to test THIO (ateganosine) in combination with Tecentriq (atezolizumab, Roche’s PD-L1 checkpoint inhibitor) for the treatment of several hard-to-treat cancers. MAIA now has supply agreements to test THIO in combination with checkpoint inhibitors from three global pharmaceutical companies, which we see as an indicator of interest for future partnerships.

PD-1 or PD-1L? That Is The Question. Checkpoint inhibitors block the interaction of the surface proteins PD-1 (programmed death receptor-1) with PD-1L (the programed death receptor-1 ligand). When the PD-1 receptor binds to the PD-1L ligand, it inhibits the immune response. Checkpoint inhibitors are monoclonal antibody drugs against PD-1 or PD-L1 that block this interaction, allowing cancer cells to be recognized by a patient’s immune system and killed.

Get the Full Report

Nutriband (NTRB/$7.79 | Price Target: $15)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Manufacturing Milestone Allows Development To Move Forward As Expected
Rating: OUTPERFORM

Preparing For AVERSA Fentanyl Clinical Testing. Nutriband and its partner Kindeva announced that it has completed commercial manufacturing processes and scale-up for AVERSA Fentanyl, its abuse-deterrent fentanyl patch. This allows the company begin manufacturing clinical supplies and filing the IND (Investigational New Drug application) for the Phase 1 clinical study within the timeframe we anticipated. Only a single Phase 1 study is needed to file the application for marketing approval.

Manufacturing Completion Is A Significant Milestone. This scale-up is a significant step that demonstrates the ability to apply Kindeva’s transdermal patch technology for commercial scale production of AVERSA Fentanyl patches. We expect the IND filing to be completed shortly, with clinical testing to follow as expected.

Get the Full Report

Noble Capital Markets Research Report Wednesday, June 18, 2025

Companies contained in today’s report:

GoHealth (GOCO)/OUTPERFORM – Noble Virtual Conference Highlights
Vince Holding Corp. (VNCE)/OUTPERFORM – Mitigates Tariff Risks Much Faster Than Expected

GoHealth (GOCO/$5.46 | Price Target: $25)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Highlights from Noble’s Emerging Growth Virtual Conference. Vijay Kotte, CEO, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Kotte highlighted the company’s proprietary technology, consumer-centric Medicare policy platform, and gave an update on recent developments. A rebroadcast is available here.

Purpose-built technology. Mr. Kotte emphasized the company’s use of proprietary machine learning tools alongside licensed agents to tailor recommendations to each consumer’s needs. With Medicare beneficiaries typically choosing from 40–50 plans, this technology plays a key role in efficiently identifying the most suitable options.

Get the Full Report

Vince Holding Corp. (VNCE/$1.48 | Price Target: $2.5)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Mitigates Tariff Risks Much Faster Than Expected
Rating: OUTPERFORM

Solid Q1 results. the company reported Q1 revenue of $57.9 million and an adj. EBITDA loss of $3.0 million, both of which were better than our estimates of $56.0 million and a loss of $5.5 million, respectively. Notably, while revenue and adj. EBITDA are both modestly lower than the prior year period; we view the Q1 results favorably, given the company’s ability to manage the uncertain tariff outlook.

Tariff mitigation. The company highlighted that it has been taking steps to reduce its exposure to China, currently roughly 60% of its cost of goods sold. Notably, the company is sourcing from other countries and expects that China will be roughly 25% of its cost of goods by the end of 2025. The company has leadership located in the sourcing countries to ensure product quality. 

Get the Full Report

Noble Capital Markets Research Report Tuesday, June 17, 2025

Companies contained in today’s report:

GeoVax Labs (GOVX)/OUTPERFORM – EMA Allows GEO-MVA To Leapfrog To Phase 3 Trial In EU
Kratos Defense & Security (KTOS)/OUTPERFORM – New Award and Expansion; Raising PT
Ocugen (OCGN)/OUTPERFORM – Stargardt Disease Program Moves To Phase 2/3 Trial
SKYX Platforms (SKYX)/OUTPERFORM – Noble Virtual Conference Highlights
The GEO Group (GEO)/OUTPERFORM – New USMS Transportation Contract

GeoVax Labs (GOVX/$1.32 | Price Target: $10)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
EMA Allows GEO-MVA To Leapfrog To Phase 3 Trial In EU
Rating: OUTPERFORM

GEO-MVA Gets An Accelerated Pathway To European Approval. GeoVax announced that it has received guidance from the EMA (European Medicines Agency) that provides an accelerated path to approval for GEO-MVA, its modified vaccinia ankara (MVA) based vaccine for smallpox/Mpox. It will only be required to conduct immune-bridging and toxicity studies before moving directly to Phase 3. This cuts several years from development time and saves many millions of dollars in clinical expenses.

Only Phase 3 Will Be Needed. The Committee for Medicinal Products for Human Use (CHMP) of the EMA stated that only requirements before beginning a Phase 3 study will be a non-clinical immuno-bridging and toxicity studies. No Phase 1 or Phase 2 studies are required. An MAA regulatory application can be submitted after a single, Phase 3 immuno-bridging study against the approved MVA vaccine (Imvanex or Jynneos, from Bavarian Nordic). The proposed endpoints of the study would be demonstration of immunogenicity to show non-inferiority.

Get the Full Report

Kratos Defense & Security (KTOS/$41.21 | Price Target: $44)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Hans Baldau hbaldau@noblefcm.com |
New Award and Expansion; Raising PT
Rating: OUTPERFORM

New Award. Kratos was awarded a $25 million task order under the Command and Control System-Consolidated Sustainment and Resiliency contract with the U.S. Space Force Space Systems Command to support ground system capabilities for  Evolved Strategic Satellite Communications (ESS). The ESS system will provide the survivable and endurable satellite communications capability for the Nuclear Command, Control, and Communications mission in all operational environments.

Details. The task order has a 34-month period of performance, which began on  March 14th and will conclude on  November 30, 2027. This was accomplished under the C-SAR single-award indefinite delivery/indefinite quantity (IDIQ) contract awarded to Kratos on  November 15, 2023. The C-SAR IDIQ contract has a maximum value of  $579 million to cover task/delivery orders to support operations, sustainment, enhancements, and constellation capacity.

Get the Full Report

Ocugen (OCGN/$1.16 | Price Target: $8)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
Stargardt Disease Program Moves To Phase 2/3 Trial
Rating: OUTPERFORM

OCU410ST Cleared To Begin Confirmatory Trial. Ocugen announced that the FDA has approved its IND amendment to allow OCU410ST to begin its Phase 2/3 pivotal confirmatory trial. This will become the second Ocugen product to move into a Phase 2/3 confirmatory trial, and keeps the company on schedule to meet its goal of submitting three BLAs in the three years between 2026-28.

Brief Description of Stargardt Disease. Stargardt disease is a rare autosomal recessive disease caused by mutations in the ABCA4 gene in the retina. Progressive loss of photoreceptor cells in the retina typically starts at a young age, leading to blindness. Ocugen has received Orphan Drug designation and Rare Pediatric Disease Designation (RPDD) for diseases associated with ABCA4 diseases, including Stargardt, retinitis pigmentosa 19, and cone-rod dystrophy 3.

Get the Full Report

SKYX Platforms (SKYX/$1.26 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Highlights from Noble’s Emerging Growth Virtual Conference. Lenny Sokolow, Co-CEO, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Sokolow discussed the company’s innovative technology, commercial partnerships, and its quest for mandatory standardization with the NEC, among other topics. A rebroadcast is available here.

Mandatory standardization efforts getting a boost. Management remains optimistic about its push for mandatory standardization, citing recent backing from a prominent government safety leader. The company’s “Code Team” expects further support from key safety organizations to advance its ceiling receptacle technology as a regulatory standard.

Get the Full Report

The GEO Group (GEO/$24.9 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
New USMS Transportation Contract
Rating: OUTPERFORM

USMS Contract. The GEO Group, through its GEO Transport subsidiary, has entered into a new 5-year contract, including option periods, with the U.S. Marshals Service (USMS) for the provision of secure transportation and contract detention officer services across three service regions covering 26 federal judicial districts and spanning 14 states. The new contract highlights the Company’s diversified service platform, in our view, which provides the Company with numerous growth avenues.

Impact. The new contract is expected to generate up to approximately $147 million over the five-year period, or up to approximately $29 million in annualized revenues per full-year of operations, with margins consistent with GEO’s Managed-Only services contracts, which average approximately 15%.

Get the Full Report

Noble Capital Markets Research Report Monday, June 16, 2025

Companies contained in today’s report:

Sky Harbour Group (SKYH)/OUTPERFORM – Noble Virtual Conference Highlights
Superior Group of Companies (SGC)/OUTPERFORM – Noble Virtual Conference Highlights
Travelzoo (TZOO)/OUTPERFORM – A New Addition To The Russell

Sky Harbour Group (SKYH/$9.73 | Price Target: $23)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Highlights from Noble’s Emerging Growth Virtual Conference. Tim Herr, Senior Vice President of Finance, presented at Noble’s Virtual Equity conference June 4 & 5th. Mr. Herr highlighted the company’s high-margin leasing model, market opportunity, and strategic initiatives. A rebroadcast is available here.

Attractive unit economics driven by high-margin lease model. Sky Harbour secures long-term airport ground leases at highly favorable rates, often below $1 per square foot annually. Although only 25–33% of each site is convertible into revenue-generating hangar space, that portion can lease for $40 or more per square foot, creating a substantial economic spread.

Get the Full Report

Superior Group of Companies (SGC/$9.79 | Price Target: $16)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Highlights its investment merits. On June 5, the company presented at the Noble Virtual Conference to the investment community. The presentation conducted by Michael Benstock, CEO, and Mike Koempel, CFO, highlighted the company’s diverse business segments, favorable history of growth, and solid financial position. A replay of the presentation is available for viewing here.

Diverse business segments. The company operates three distinct business segments: Healthcare Apparel, Branded Products, and Contact Centers. Importantly, all three of the company’s segments have favorable organic growth opportunities, are profitable, and have compelling acquisition target opportunities. Furthermore, the company has a solid history of growth, with consolidated revenue growing at an 8% CAGR from 2019 through 2024.

Get the Full Report

Travelzoo (TZOO/$12.5 | Price Target: $28)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
A New Addition To The Russell
Rating: OUTPERFORM

Joining the Russell. On June 10, the company announced that it is expected to join the Russell 3000 Index at market open on June 27. Notably, membership in the Russell 3000 Index, which remains active for one year, provides the company with automatic inclusion in the Russell 2000 Index. 

Improved share visibility. In our view, joining the Russell Indices could provide a meaningful impact for the TZOO shares. Notably, we believe the inclusion in the Russell indices is likely to enhance the company’s share visibility among institutional investors and has the potential to increase trading volume, improve share liquidity, and introduce new investors to the company. As such, we view the development favorably.

Get the Full Report

Noble Capital Markets Research Report Friday, June 13, 2025

Companies contained in today’s report:

Bitcoin Depot (BTM)/OUTPERFORM – Pelicoin Pick-Up: A Nice Tuck-In Acquisition
FreightCar America (RAIL)/OUTPERFORM – Modest Adjustments to Our 2025 Quarterly Estimates; No Change to Full Year Projections
Snail (SNAL)/OUTPERFORM – Noble Virtual Conference Highlights

Bitcoin Depot (BTM/$6.25 | Price Target: $9)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Pelicoin Pick-Up: A Nice Tuck-In Acquisition
Rating: OUTPERFORM

Bolsters its southern operations. On June 11, the company announced that it had acquired the assets of Pelicoin, a crypto ATM company with operations in the Gulf South (particularly MS, AL, TX, TN). The additional kiosks, which we believe to be roughly 50, are expected to be fully integrated within several weeks.

Industry consolidation. In our view, the acquisition demonstrates the attractive industry consolidation opportunity for the company. Notably, the Pelicoin acquisition marks the second time in the last 18 months that the company has opportunistically added to its kiosk fleet. In April 2024, the company acquired 2,300 kiosks at a 50% discount from a defunct operator. We believe, with its healthy cash balance of $35 million (as of 3/31/25), the company is well positioned to continue to consolidate the industry as opportunities arise.

Get the Full Report

FreightCar America (RAIL/$8.9 | Price Target: $13.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Modest Adjustments to Our 2025 Quarterly Estimates; No Change to Full Year Projections
Rating: OUTPERFORM

Updating estimates. While we are maintaining our 2025 rail car delivery estimate of 4,710, we have lowered our second quarter expectations to 850 from 950 and increased our third quarter estimate to 1,790 from 1,690. Our 2025 EBITDA and EPS estimates are unchanged at $45.9 million, and $0.47, respectively. However, our second and third quarter EPS estimates are $0.06 and $0.20, respectively, compared to our prior estimates of $0.07 and $0.19.

Flexible production schedule. With FreightCar’s asset-based lending facility, the company has greater flexibility to manage its production schedule, given that it can borrow against inventory. The company has the ability to produce rail cars associated with firm orders and hold them for delivery to suit customer needs. 

Get the Full Report

Snail (SNAL/$1.25 | Price Target: $4)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. On June 4, the company presented at the Noble Virtual Conference to the investment community. The presentation conducted by Heidy Chow, CFO, and Peter Lin, Sr. Manager, FP&A, highlighted the company’s release roadmap, unique product offerings, and portfolio diversification. A replay of the presentation can be viewed here.

Favorable release roadmap. The company has a busy release roadmap for 2025, which includes a 10th-anniversary expansion pack for ARK: Survival Evolved, a new expansion pack for ARK: Survival Ascended, and the release of Bellwright on Xbox in Q4. Additionally, nine new gaming titles are slated for 2025, including Robots at Midnight, Honeycomb, and Echoes of Elysium, which could have breakout potential. Additionally, the company recently expanded into new entertainment categories to further expand its portfolio.

Get the Full Report

Noble Capital Markets Research Report Thursday, June 12, 2025

Companies contained in today’s report:

CoreCivic, Inc. (CXW)/OUTPERFORM – An Acquisition
GDEV (GDEV)/OUTPERFORM – Strategic Initiatives Gain Traction
Metals & Mining (Metals & Mining) – Metals and Mining Spotlight: Rare Earth Elements

CoreCivic, Inc. (CXW/$21.44 | Price Target: $28)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
An Acquisition
Rating: OUTPERFORM

Acquisition. CoreCivic is expanding its Safety Segment with the proposed acquisition of The Farmville Detention Center in Farmville, Virginia, about 60 miles west of Richmond. Constructed in 2010, Farmville is a 736-bed facility that provides transportation, care, and civil detention services to adult male noncitizens through an Intergovernmental Service Agreement between Prince Edward County, Virginia, and U.S. Immigration & Customs Enforcement (“ICE”), which expires in March 2029.

Details. CoreCivic is paying $67 million for Farmville, or about $91,000 per bed. The transaction is expected to be funded with cash on hand and borrowings under the Company’s revolving credit facility. The acquisition is expected to close effective July 1st and will add approximately $40 million of incremental revenue on an annual basis. Using the Safety segment’s average 2024 operating margin, Farmville could add nearly $10 million of segment operating income on an annual basis.

Get the Full Report

GDEV (GDEV/$21.21 | Price Target: $70)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Strategic Initiatives Gain Traction
Rating: OUTPERFORM

Solid Q1 Results. The company reported Q1 revenue of $97.0 million and adj. EBITDA of $15.6 million, both of which easily surpassed our estimates of $87.0 million and a loss of $0.6 million, respectively. Notably, while revenue decreased 9% from last year, adj. EBITDA was up substantially from a loss of roughly $1.0 million. The improvement in adj. EBITDA was largely driven by the company’s efficient use of marketing spend and focus on profitability.

Key operating metrics. Bookings and monthly paying users decreased by 25% and 26%, respectively, compared to the prior year period, but the decrease was expected as the company is focused on improving the quality of gameplay and not over-monetizing its user base. For example, average bookings per paying user (ABPPU) increased from $88 in Q1’24 to $90 in Q1’25, despite a decrease in monthly paying users. 

Get the Full Report

Metals & Mining
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Metals and Mining Spotlight: Rare Earth Elements

Demand for rare earth elements expected to grow. Demand for rare earth elements is expected to grow meaningfully through 2030 and beyond, driven by electric vehicles, wind turbines, grid upgrades, and advanced defense technologies. According to the IEA, global rare earth demand could double by 2050 under a net-zero scenario, underscoring the growing strategic relevance in the global energy transition.

China dominates the REE market. According to the 2024 edition of the Energy Institute Statistical Review of World Energy, China accounted for 67.9% of rare earth mineral production in 2023 and 38.1% of rare earth mineral reserves, while accounting for most of the midstream and downstream capacity. While mining activity is gradually diversifying, the refining stage remains concentrated. This level of concentration poses a risk to both the U.S. supply chain and national security.

Get the Full Report

Noble Capital Markets Research Report Wednesday, June 11, 2025

Companies contained in today’s report:

Century Lithium Corp. (CYDVF)/OUTPERFORM – Century Lithium Commences LIFE Offering Financing
MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – Another Arrow in the Quiver
The GEO Group (GEO)/OUTPERFORM – Some More Good News
Unicycive Therapeutics (UNCY)/OUTPERFORM – FDA Finds Deficiencies At Third-Party Manufacturing Subcontractor – Approval Could Be Delayed
Xcel Brands (XELB)/OUTPERFORM – Positioned For A Much Bigger Company

Century Lithium Corp. (CYDVF/$0.21 | Price Target: $2.3)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Century Lithium Commences LIFE Offering Financing
Rating: OUTPERFORM

LIFE offering. Century Lithium has commenced an offering, under the Listed Issuer Financing Exemption (LIFE), to raise a minimum of C$2,000,000 and a maximum of C$5,000,000 with an offering of up to 16,666,667 units at a price of C$0.30 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one common share at an exercise price of C$0.45 for a period of 24 months following the issuance of the units. After selling commissions, fees, and estimated offering costs, the company expects to receive net proceeds of C$1,810,000 to C$4,600,000.

Use of net proceeds. Net proceeds from the financing will be used to complete an updated feasibility study for the company’s Angel Island Lithium Project, complete the project’s Plan of Operations, work towards National Environmental Policy Act (NEPA) compliance, and general working capital. The offering is expected to close on or about July 7 and is not expected to close in tranches.

Get the Full Report

MustGrow Biologics Corp. (MGROF/$0.71)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Another Arrow in the Quiver
Rating: MARKET PERFORM

Another Arrow. Yesterday, MustGrow added another arrow to its NexusBioAg product quiver with the signing of a distribution agreement with Phospholutions Inc., whereby MustGrow will sell Phospholutions’ RhizoSorb product in Canada. The new agreement further broadens NexusBioAg’s product offerings in Canada.

RhizoSorb. Phospholutions’ mission is to enhance global phosphorus use, a critical fertilizer for food production. Phosphorus is the second most used nutrient in global food production. RhizoSorb was developed to cut costs and reduce the environmental impact of fertilizer use by releasing nutrients in the soil more efficiently. The product has been through over 500 trials, including over 400 field trials. Notably, Phospholutions has signed a distribution agreement with The Andersons (NASDAQ:ANDE) for RhizoSorb distribution in the U.S.

Get the Full Report

The GEO Group (GEO/$26.96 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Some More Good News
Rating: OUTPERFORM

Favorable Adelanto Outcome. The GEO Group received some more good news yesterday with the U.S. District Court, Central District of California, approving a settlement that allows for immediate full intake at GEO’s 1,940-bed Adelanto ICE Processing Center in California. Recall, previous court rulings had limited the use of Adelanto based on the then prevailing COVID-19 conditions.

Another Uplift. Under a January 20025 ruling, the Court had allowed the facility to increase its population cap to 475 detainees. At full occupancy and under the current contract, GEO would see an uplift in revenue of some $31 million, with margins consistent with other Company-owned Secure Service facilities. Adding in Monday’s D. Ray James announcement, GEO could be looking at $100 million of additional revenue and approximately $26 million of net operating income on an annual basis.

Get the Full Report

Unicycive Therapeutics (UNCY/$0.53 | Price Target: $6)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
FDA Finds Deficiencies At Third-Party Manufacturing Subcontractor – Approval Could Be Delayed
Rating: OUTPERFORM

Approval May Come After The PDUFA Date Of June 28. Unicycive announced that an FDA inspection has found deficiencies with the cGMP (certified Good Manufacturing Practice) compliance at a third-party manufacturing subcontractor. The company’s product, OLC, is manufactured by a contract manufacturer with other subcontractors. The deficiency does not involve the active pharmaceutical compound (APC) and may be related to final finishing and packaging operations.

Good News and Bad News. The FDA stated that the manufacturing deficiencies must be resolved before product label discussions can proceed. We interpret this to mean that the FDA review of the clinical data has been completed, the manufacturing inspection was conducted, and product labeling remains as the final step before approval. Although the manufacturing deficiencies have stopped the labeling discussion, we expect NDA approval when corrected.

Get the Full Report

Xcel Brands (XELB/$1.91 | Price Target: $12)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Positioned For A Much Bigger Company
Rating: OUTPERFORM

Q1 results. First quarter results indicated a modest improvement from Q4, but it was a slow start to the year. First quarter revenues were $1.3 million, and the company reported an adj. EBITDA loss of $0.7 million from continuing operations. We believe the company is well positioned to benefit from a number of favorable developments, including the launch of new brands, contributions from Halston, and a lower cost base.

Strategic partnerships. Notably, the company announced a series of new strategic partnerships this year with Jenny Martinez, Gemma Stafford, and Cesar Millan. These new strategic partnerships expand the company’s product offerings into pet products, bakeware, kitchenware, and home essentials. Furthermore, the new celebrity partnerships bring a large number of social media followers, which supports the company’s effort to reach 100 million social media followers in 2026.

Get the Full Report

Noble Capital Markets Research Report Tuesday, June 10, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Maximizing the Value of Comstock’s Mining Assets
Graham (GHM)/OUTPERFORM – A Record Year With Momentum Continuing to Build
Nicola Mining Inc. (HUSIF)/OUTPERFORM – Nicola Receives a Multi-Year Exploration Permit for the Treasure Mountain Project
Townsquare Media (TSQ)/OUTPERFORM – We Don’t Live In That Neighborhood

Comstock (LODE/$3.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Maximizing the Value of Comstock’s Mining Assets
Rating: MARKET PERFORM

Amended agreement with Mackay Precious Metals. Comstock Inc. amended the membership interest purchase agreement to sell 100% of its northern most patented and unpatented mining claims, mineral exploration rights and town lots owned by Comstock Northern Exploration, LLC, plus the 25% issued and outstanding membership interest that Comstock owns in Pelen LLC to Mackay Precious Metals Inc. Consideration includes $2.95 million in cash plus a 1.5% NSR production royalty associated with the properties.

More favorable terms. The amendment increases the sale price to $2.95 million in cash from the previous $2.75 million in both cash and stock, thus increasing the cash component of the transaction by $1.2 million. Comstock previously received $1.0 million in cash. The remaining $1.95 million is due in a series of payments in June, July, and ending on or before August 30. Additionally, Mackay will transfer approximately 300 acres of patented and unpatented mining properties in Lyon County, Nevada, that are adjacent to and expand the area of Comstock’s Dayton Consolidated and Spring Valley mineral claims and lands for no consideration.

Get the Full Report

Graham (GHM/$44.66 | Price Target: $52)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Hans Baldau hbaldau@noblefcm.com |
A Record Year With Momentum Continuing to Build
Rating: OUTPERFORM

4Q25 Results. Revenue rose 21% to $59.3 million versus $49.1 million in 4Q24 and our $56 million estimate. Gross margin was up 110 basis points to 27%. We were at 25%. Graham reported adjusted EBITDA of $7.65 million, up 159% y-o-y, and above our $5.4 million projection. GAAP and adjusted EPS were $0.40 and $0.43, respectively, compared to $0.12 and $0.15, respectively, last year. We were at $0.26 and $0.26.

Business Environment. Graham’s business environment remains favorable, as evidenced by the recent follow on Navy award. Increased Defense budgets and being in the right space should lead to additional revenue from the Defense sector. Space and Energy continue to have positive futures also, in our opinion.

Get the Full Report

Nicola Mining Inc. (HUSIF/$0.33 | Price Target: $0.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Nicola Receives a Multi-Year Exploration Permit for the Treasure Mountain Project
Rating: OUTPERFORM

Treasure Mountain. Nicola Mining’s (TSX.V: NIM, OTCQB: HUSIF) Treasure Mountain Project is a 100% owned high-grade silver, lead, and zinc past-producing underground mine located 29 kilometers northeast of Hope, British Columbia. It offers significant exploration potential and has a valid permit (M-239) for mining operations through April 26, 2032, that permits the company to mine up to 60,000 tonnes per year. The company holds 31 contiguous mineral claims over an area of approximately 2,200 hectares and one mining lease covering 335 hectares, including 248 hectares of historic workings.

Receipt of exploration permit. On June 4, Nicola Mining received a multi-year area-based (MYAB) exploration permit to conduct extensive exploration at Treasure Mountain. The MYAB permit allows the company to carry out exploration activities, including 30 drill holes, 1,400 meters of trenching, 4,500 meters of trail building, and 20 kilometers of geophysical surveys over the next five years within certain boundaries of the project.

Get the Full Report

Townsquare Media (TSQ/$7.28 | Price Target: $21)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
We Don’t Live In That Neighborhood
Rating: OUTPERFORM

Highlights from Noble’s Emerging Growth Virtual Conference. This report highlights Townsquare Media’s participation in Noble’s Virtual Equity conference June 4 & 5th. Bill Wilson, CEO, Stuart Rosenstein, CFO, and Claire Yanicay, Executive VP IR, provided insights on the company’s Digital strategy and favorable revenue and growth outlook. In addition, management highlighted its goal to reduce debt leverage. A rebroadcast is available here.  

Digital to approach 70% of total company revenues. Currently, Digital accounts for roughly 55% of total company revenues and 55% of cash flow. Management indicated that Digital should continue to grow at favorable growth rates, with expected small declines in its legacy broadcast business. As such, management stated that total Digital revenues should approach 70% of total company revenue and cash flow contributions in the long term. 

Get the Full Report

Noble Capital Markets Research Report Monday, June 9, 2025

Companies contained in today’s report:

CoreCivic, Inc. (CXW)/OUTPERFORM – Noble Virtual Conference Highlights
FAT Brands (FAT)/OUTPERFORM – Noble Virtual Conference Highlights
Kelly Services (KELYA)/OUTPERFORM – Noble Virtual Conference Highlights
NN (NNBR)/OUTPERFORM – Noble Virtual Conference Highlights
ONE Group Hospitality (STKS)/OUTPERFORM – Noble Virtual Conference Highlights
Resources Connection (RGP)/OUTPERFORM – Noble Virtual Conference Highlights
Steelcase (SCS)/OUTPERFORM – Noble Virtual Conference Highlights
The GEO Group (GEO)/OUTPERFORM – Lawton Sale and D. Ray James Approval
Titan International (TWI)/OUTPERFORM – Noble Virtual Conference Highlights

CoreCivic, Inc. (CXW/$21.98 | Price Target: $28)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. CoreCivic CFO David Garfinkle and Vice President Finance Brian Hammonds presented at the Noble Virtual Conference. Highlights included increased demand, long-term trends, and return of capital. A rebroadcast is available at https://www.channelchek.com/videos/corecivic-cxw-noble-capital-markets-virtual-conference-replay

Increased Demand. As regular readers know, CoreCivic has seen increased demand for its services from ICE. The Company already has received new awards for beds and expects to re-open currently idled facilities for ICE. Increased occupancy could drive significant earnings growth. Occupancy in 1Q25 was 77%, still below the low 80% range in 2018/19. The Company showed various illustrative potential for increased demand that could add $73-$131 million of additional NOI.

Get the Full Report

FAT Brands (FAT/$2.46 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. FAT Brands Chairman Andy Wiederhorn and Co-CEO Ken Kuick presented at the Noble Virtual Conference. Highlights included the new store pipeline, Twin Hospitality, and factory utilization. A rebroadcast is available at https://www.channelchek.com/videos/fat-brands-fat-noble-capital-markets-virtual-conference-replay

Pipeline. FAT Brands new store pipeline consists of approximately 1,100 units already paid for by franchisees, which will add some $50-60 million of incremental EBITDA once opened. With some 250 new unit agreements per year and some 100+ new openings per year, we expect the pipeline to be a key driver of financial performance going forward.

Get the Full Report

Kelly Services (KELYA/$11.91 | Price Target: $27)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. Kelly Services CFO Troy Anderson and IR Scott Thomas presented at the Noble Virtual Conference. Highlights included the value creation opportunity, increased margins, and capital allocation. A rebroadcast is available at https://www.channelchek.com/videos/kelly-services-kelya-noble-capital-markets-virtual-conference-replay.

Value Creation Opportunity. A key chart in Kelly’s presentation highlights how the implied value of Kelly’s individual businesses and their valuation multiples relative to peers implies considerable upside potential. Based on Kelly’s current enterprise value and the historic valuation multiple of the peer group, management believes KELYA shares have a nearly 100% upside opportunity at this time.

Get the Full Report

NN (NNBR/$2.11 | Price Target: $6)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. NN CEO Harold Bevis, CFO Chris Bohnert, and COO Tim French presented at the Noble Virtual Conference. Highlights included tariffs, diversifying end markets, and China operations. A rebroadcast is available at https://www.channelchek.com/videos/nn-inc-nnbr-noble-capital-markets-virtual-conference-replay.

Tariff Impact. With production sourced and sold in-country, the direct impact of tariffs on NN is expected to be minimal. The Company has seen some modest indirect impact, mostly related to deferred decision making on the part of clients and/or consumers. Once tariffs have stabilized, we expect any indirect impacts to be minimal.

Get the Full Report

ONE Group Hospitality (STKS/$3.55 | Price Target: $5)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. We held a fireside chat with ONE Group CEO Manny Hilario and CFO Tyler Loy at the Noble Virtual Conference. Highlights included its leading position in Vibe dining, growth opportunities, and asset light development. A rebroadcast is available at https://www.channelchek.com/videos/the-one-group-stks-noble-capital-markets-virtual-conference-replay.

A Leader. With approximately 165 locations, ONE Group is a leader in Vibe dining through its ownership of STK, Benihana, Kona Grill, and RA Sushi. Notably, Vibe dining customers tend to generate higher average checks while only remaining in the restaurant for slightly longer than traditional restaurant customers.

Get the Full Report

Resources Connection (RGP/$5.14 | Price Target: $15)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. Resources Connection CEO Kate Duchene and CFO Jenn Ryu presented at the Noble Virtual Conference. Highlights included the business transformation, the flexible cost model, and pristine balance sheet. A rebroadcast is available at https://www.channelchek.com/videos/rgp-rgp-noble-capital-markets-virtual-conference-replay.

Transformation. RGP’s business transformation has uniquely positioned the Company to capitalize on shifting demand in its end markets. RGP’s diversified client base and high retention reduce risk and drive long-term value, in our view. The Company’s business is diversified across industries, regions, and service lines, while high retention is growing the lifetime value of clients.

Get the Full Report

Steelcase (SCS/$10.35 | Price Target: $16)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. Steelcase CFO Dave Sylvester and Director of IR Mike O’Meara presented at the Noble Virtual Conference. Highlights included return-to-office (RTO) trends, the international business, and tariffs. A rebroadcast is available at https://www.channelchek.com/videos/steelcase-scs-noble-capital-markets-virtual-conference-replay.

RTO Trends. While overall office occupancy improvement trends have somewhat flattened, Steelcase’s key end market, firms in Class A office space, are improving as more large companies are becoming more aggressive about employees returning to the office. And split working environments can be a benefit to Steelcase as employees need to set up work-from-home offices. Steelcase continues to lead the transformation of the workplace.

Get the Full Report

The GEO Group (GEO/$26.95 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Lawton Sale and D. Ray James Approval
Rating: OUTPERFORM

Lawton Sale. The GEO Group announced it has entered into a purchase agreement to sell its Company-owned Lawton, OK, facility to the Oklahoma Department of Corrections for $312 million. This is one of two facilities GEO management had indicated were up for sale. The sale is expected to close by the end of July 2025.

Value Affirming. The Lawton sale re-affirms our belief in the value of GEO’s real estate assets, a value that significantly exceeds the current stock price. Based on the reported 2,682 beds, the purchase price is equivalent to $116,000/bd. With some 43,000 owned beds in the Safety segment alone, the potential value of the segment real estate would be $5 billion. We do not expect the sale to have a significant impact on reported EBITDA.

Get the Full Report

Titan International (TWI/$8.11 | Price Target: $11)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Noble Virtual Conference Highlights
Rating: OUTPERFORM

Noble Virtual Conference. We held a fireside chat with Titan CEO Paul Reitz at the Noble Virtual Conference. Highlights included the elevated baseline,  innovation, and tariffs. A rebroadcast is available at https://www.channelchek.com/videos/titan-international-twi-noble-capital-markets-virtual-conference-replay.

Elevated Baseline. Titan’s multi-year strategic transformation has elevated the baseline for the Company. An optimized product portfolio, strong customer relationships, expanded aftermarket business, and long-term tailwinds have increased Titan’s earnings power to $250-$300 million of adjusted EBITDA mid-cycle.

Get the Full Report

Noble Capital Markets Research Report Friday, June 6, 2025

Companies contained in today’s report:

EuroDry (EDRY)/MARKET PERFORM – Sustained Market Weakness Weighs on Performance
MAIA Biotechnology (MAIA)/OUTPERFORM – THIO Update Shows Another Increase In Overall Survival

EuroDry (EDRY/$8.28)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Sustained Market Weakness Weighs on Performance
Rating: MARKET PERFORM

First quarter financial results. Eurodry Ltd. reported an adjusted first quarter net loss of $5.7 million, or ($2.07) per share, compared to a loss of $3.2 million, or ($1.18) per share, during the same period last year. Adjusted EBITDA came in at a loss of $1.0 million, down from a gain of $2.1 million during the first quarter of last year. While revenue was slightly above our expectations, operating expenses were approximately $2.0 million higher than estimated due to increased repair costs. Overall, the quarterly results reflected the ongoing market challenges as charter rates remain near five-year lows due to challenging supply and demand trends.

Updating 2025 estimates. Based on the lower-than-expected first quarter results and management’s outlook, we are lowering our full year 2025 adjusted EBITDA and earnings per share (EPS) estimates to $9.3 million and ($3.79), respectively, down from $19.6 million and ($0.43). While we expect the second quarter to show a slight rebound, the weak market conditions are expected to persist and could constrain rates through the balance of the year.

Get the Full Report

MAIA Biotechnology (MAIA/$1.95 | Price Target: $14)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
THIO Update Shows Another Increase In Overall Survival
Rating: OUTPERFORM

New THIO-101 Update Presented AT ASCO. MAIA presented updated data from its THIO-101 trial showing median overall survival increased as more patients advanced through treatment. Data presented showed a median overall survival of 17.8 months for patients receiving the combination of THIO and the PD-1 inhibitor, Libtayo (cemiplimab, a checkpoint inhibitor from Regeneron), an increase from 16.9 months reported in January 2025.

Survival Improved As More Patients Completed The Study. Updated data was presented at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting, with more patients treated for longer periods. The median overall survival reported was 17.8 months compared with the expected survival of 5.8 months for standard of care therapy. This was an improvement from 16.9 months (n=22 patients) reported in January 2025 and 10.6 months (n=19 patients) reported in August 2024.

Get the Full Report

Noble Capital Markets Research Report Thursday, June 5, 2025

Companies contained in today’s report:

Euroseas (ESEA)/OUTPERFORM – Increasing 2025 Estimates, Conference Highlights
Xcel Brands (XELB)/OUTPERFORM – Positive Cash Flow Outlook Still In Tact

Euroseas (ESEA/$39.26 | Price Target: $51)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Increasing 2025 Estimates, Conference Highlights
Rating: OUTPERFORM

New M/V Emmanuel P time charter contract. Euroseas Ltd. secured a new time charter contract for its 4,250 twenty-foot-equivalent (TEU) intermediate containership, M/V Emmanuel P, for a minimum of 36 months to a maximum period of 38 months, at the option of the charterer, at a gross daily rate of $38,000. The new contract represents a significant improvement compared to the previous rate of $21,000 per day. Following the completion of a scheduled drydock and installation of energy saving devices, the new charter is expected to commence upon delivery of the vessel from the shipyard in the first half of September.

Agreement to sell the M/V Marcos. Euroseas Ltd. recently signed an agreement to sell the M/V Marcos V, a 6,350 twenty-foot-equivalent unit (TEU) intermediate containership, to an unaffiliated third party for $50 million. The vessel will be delivered to the buyer in October 2025. ESEA expects to recognize a gain of ~$8.5 million, or $1.20 per share. The vessel was acquired in the fourth quarter of 2021 for $40 million. During its ownership, Euroseas Ltd. realized more than five times its original equity investment.

Get the Full Report

Xcel Brands (XELB/$2.31 | Price Target: $15)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Positive Cash Flow Outlook Still In Tact
Rating: OUTPERFORM

Q1 Results. First quarter results indicated a modest improvement from Q4, but it was a slow start to the year. First quarter revenues were $1.3 million, and the company reported an adj. EBITDA loss of $0.7 million from continuing operations. We believe the company is well positioned to benefit from a number of favorable developments, including the launch of new brands, contributions from Halston, and a lower cost base.

Positive outlook. The company indicated that it plans to be adj. EBITDA $1 million to $2.5 million positive for full year 2025 in spite of the potential impact of trade policies and disruption from headquarter consolidation at HSN and QVC. The outlook is supported by significant cost reductions that are expected to be at a run rate of $2.5 million per quarter and building royalty revenue from GIII and its Halston brand. Most of the trade policy uncertainty is focused on the second half of the year. 

Get the Full Report

Noble Capital Markets Research Report Wednesday, June 4, 2025

Companies contained in today’s report:

Titan International (TWI)/OUTPERFORM – An Off Road Leader; Initiating Research Coverage

Titan International (TWI/$7.6 | Price Target: $11)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
An Off Road Leader; Initiating Research Coverage
Rating: OUTPERFORM

Initiation of Research Coverage. We are initiating research coverage of Titan International with an Outperform rating and an $11 price target. Titan is a worldwide leader in the manufacture of off road wheels, tires, and undercarriages for the agriculture, construction, mining, and consumer space.

Transformation. Titan has undergone a strategic transformation since 2019. Management has restructured the Company, eliminating non-core assets, improving the balance sheet, and diversifying the business through acquisitions. Though still subject to cyclicality of its end markets, we believe Titan is well positioned to capitalize on improving end market demand.

Get the Full Report

Noble Capital Markets Research Report Tuesday, June 3, 2025

Companies contained in today’s report:

Codere Online (CDRO)/OUTPERFORM – Satisfies Listing Requirements
Nicola Mining Inc. (HUSIF)/OUTPERFORM – Switching into High Gear

Codere Online (CDRO/$7.25 | Price Target: $14)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Satisfies Listing Requirements
Rating: OUTPERFORM

Files 20-F with SEC. On June 2, the company announced the filing of its 2024 annual report with the SEC. As a reminder, the company was not in compliance with Nasdaq listing requirements regarding the timely filing of financial results and requested a hearing to review the delisting determination. The issue started with a change in the company’s auditors. 

Satisfying listing requirements. Notably, with the filing of its 20-F, the company believes it has regained compliance with the Nasdaq listing requirements and does not anticipate the hearing requested on May 22 will be necessary. Importantly, the filing puts the company back on track with its financial reporting.

Get the Full Report

Nicola Mining Inc. (HUSIF/$0.32 | Price Target: $0.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Switching into High Gear
Rating: OUTPERFORM

First quarter 2025 financial results. Nicola Mining (TSX.V: NIM, OTCQB: HUSIF) reported a first quarter 2025 loss of C$475,808 or C$(0.00) per share compared to a loss of C$1,028,129 or $(0.01) per share during the prior year period. We had projected a loss of C$1,044,879 or C$(0.01) per share. The variance to our estimates was largely due to a gain on marketable securities. We increased our 2025 net income and EPS estimates to C$8,803,755 and C$0.05 per share, respectively, from C$7,724,367 and C$0.04. We updated our commodity grade assumptions, along with higher metals price estimates based on actual April and May pricing and CME futures settlements for the remainder of the year.

Mill operations to commence shortly. We expect Nicola Mining to commence milling operations on or around June 15. On May 11, Talisker Resources Ltd. (TSX: TSK, OTCQX: TSKFF) began trucking run of mine material from its Mustang Mine to Nicola’s Craigmont Mill in British Columbia. Approximately 2,000 tonnes of ore had been delivered as of June 1, and we expect a stockpile of 2,500 to 3,000 tonnes prior to the mill commencing operations.

Get the Full Report

Noble Capital Markets Research Report Monday, June 2, 2025

Companies contained in today’s report:

Aurania Resources (AUIAF)/OUTPERFORM – Primed for Progress
DLH Holdings (DLHC)/OUTPERFORM – A Steady Accumulator
Great Lakes Dredge & Dock (GLDD)/OUTPERFORM – Another New Contract
Nutriband (NTRB)/OUTPERFORM – 1Q26 Results Within Expectations
The GEO Group (GEO)/OUTPERFORM – An ISAP Extension?

Aurania Resources (AUIAF/$0.17 | Price Target: $0.5)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Primed for Progress
Rating: OUTPERFORM

Annual general meeting. Aurania Resources will host its Annual Meeting of Shareholders at 1:30 pm ET on Thursday, June 12. Shareholders will vote to elect directors, appoint McGovern Hurley LLP as auditor for the ensuing year, and approve Aurania’s incentive stock option plan. Dr. Keith Barron, Chairman, President, and CEO, is expected to provide a brief update on activities following the formal part of the meeting. Aurania will provide a link to a video and/or audio replay of Dr. Barron’s update.

First quarter financial results. As an exploration company, Aurania does not generate revenue and incurs costs to advance its projects. During the first quarter, the company reported a net loss of C$5,106,264 or C$(0.05) per share compared to a loss of C$4,736,264 or C$(0.07) per share during the prior year period. Weighted average shares outstanding increased to 104,168,397 compared to 67,471,7737 during the first quarter of 2024. Exploration expenditures increased to C$3,949,010 compared to C$3,536,819 during the prior year period to fund activities in both Ecuador and France.

Get the Full Report

DLH Holdings (DLHC/$5 | Price Target: $10)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Steady Accumulator
Rating: OUTPERFORM

An Accumulator. Mink Brook Capital has been a steady accumulator of DLHC shares, amassing 2,164,058 DLHC shares, representing approximately 15% of the outstanding shares. Mink Brook first filed a schedule 13G back in early July 2024, disclosing a 5% holding of DLHC shares. The investment firm has continuously added to its stake since then. Mink Brook is the second largest holder of DLHC shares, only behind long-term holder Wynnefield Capital, owner of approximately 25.6% of the shares.

Who Is Mink Brook? Florida based Mink Brook was founded in May 2019 by William Mueller. Mr. Mueller had spent the past decade successfully investing and advising capital in the small-cap space. He desired to form an investment firm that would provide investors with idiosyncratic, uncorrelated returns by focusing on companies outside of major indexes. As of March 31st, the investment management firm had 32 positions with a market value of $95 million. Mink Brook’s DLH holding was the manager’s sixth largest by market cap.

Get the Full Report

Great Lakes Dredge & Dock (GLDD/$11.18 | Price Target: $14)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Hans Baldau hbaldau@noblefcm.com |
Another New Contract
Rating: OUTPERFORM

New Award. In Friday’s Department of Defense contract releases, Great Lakes was awarded a new $35.8 million dredging contract for Galveston, TX. The contract should be completed by the beginning of November 2025. We view this as Great Lakes filling in the very limited open 2025 calendar.

Empire 1 Restarted. In mid-May, the stop work order on the Empire 1 offshore wind project was lifted allowing construction activities to resume. Equinor will perform an updated assessment of the project economics in the second quarter. Empire aims to be able to execute planned activities in the offshore installation window in 2025 and reach its planned commercial operation date in 2027. Empire will engage with suppliers and regulatory bodies to reduce the impact of the stop work order. This is positive news for the still under construction Acadia.

Get the Full Report

Nutriband (NTRB/$6.5 | Price Target: $13)
Robert LeBoyer rleboyer@noblefcm.com | (212) 896-4625
1Q26 Results Within Expectations
Rating: OUTPERFORM

Net Loss of $1.4 Million Was Less Than We Expected. 1Q25 Nutriband reported a loss for 1Q26, ended April 30, 2025, of $1.4 million or $(0.12) per share. Product Sales were $0.67 million, slightly below the $0.7 million we had estimated. Importantly, the company made progress advancing its abuse-resistant AVERSA Fentanyl patch toward clinical testing. We expect future revenues to be driven by AVERSA Fentanyl and see the current product sales as a means to offset the cost of product development. Cash at the end of the quarter was $3.0 million.

Total Expenses Were Below Expectations. During the quarter, COGS were $0.4 million or 62% of sales, lower than the 70% we had expected and the 65% seen for FY2024. SG&A and R&D were both close to our estimates, with Total Expenses of $2.1 million lower than our estimate of $2.5 million. We had initially allowed for a stock offering during the quarter that would have increased the Weighted Average Shares Outstanding to 13.2 million, compared with the reported 11.1 million.

Get the Full Report

The GEO Group (GEO/$27.14 | Price Target: $35)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
An ISAP Extension?
Rating: OUTPERFORM

Enter Negotiations for Extension. On Friday, it was announced the government intends to enter into negotiations with GEO’s BI subsidiary for a one year extension of the ISAP program, which is currently effective through July 31, 2025. We would view an extension of this program as a significant positive for GEO in both the near-term and longer term.

A Positive Future? Acknowledging Friday’s release is limited to extending the current contract for a year, the verbiage used by the government contracting agency highlights the moat GEO has built around the business, suggesting the Company should be in the catbird’s seat for a longer term renewal. For example, the government states, “Market research conducted by the Office of Acquisition Management revealed that there is only one responsible source because the current contractor is uniquely positioned to maintain existing operations of the program without transitioning active program participants between contractor solutions.”

Get the Full Report

Noble Capital Markets Research Report Friday, May 30, 2025

Companies contained in today’s report:

Conduent (CNDT)/OUTPERFORM – DOGE Concerns Offer Attractive Investment Opportunity
Xcel Brands (XELB)/OUTPERFORM – Building A Sizeable Social Media Presence

Conduent (CNDT/$2.23 | Price Target: $7)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
DOGE Concerns Offer Attractive Investment Opportunity
Rating: OUTPERFORM

Investment thesis on track. We believe the company is on track to deliver on our full-year revenue and adj. EBITDA forecast, despite investor concerns around federal budget cuts, to which we believe the company has limited actual exposure. Moreover, although there may be some concerns over disruption from potential new asset sales, we anticipate that additional sales would likely focus on lower-margin business units and could help to bolster the company’s long-term cashflow margin profile.

Re-affirming full year 2025 estimates. While we are largely maintaining our full year estimates, we are fine-tuning the quarterly cadence of adj. EBITDA to better reflect seasonality. Our Q2 and Q3 adj. EBITDA estimates are raised to $33 million and $52 million, respectively, while Q4 is lowered to $54 million, reflecting factors tied to SNAP and Medicare enrollment. We expect 2026 revenue growth of 3% to $3.22 billion with adj. EBITDA margin expansion to 8.0%.

Get the Full Report

Xcel Brands (XELB/$2.57 | Price Target: $15)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
Building A Sizeable Social Media Presence
Rating: OUTPERFORM

Lackluster Q4 results. The company reported Q4 revenue of $1.2 million and an adj. EBITDA loss of $0.8 million, both of which were well below our estimates of $2.6 million and $0.2 million, respectively, as illustrated in Figure #1 Q4 Results. Notably, while Q4 results were softer than expected, the company has signed several new brands this year, which have yet to impact operating results. Importantly, the new brand launches have increased the company’s total social media following from 5 million to 45 million over the past five months, a significant step towards reaching its goal of 100 million followers.

Preliminary Q1 results. Additionally, the company provided preliminary Q1 results of $1.33 million in revenue, a decrease from $2.18 million last year, and an expected net loss of roughly $2.67 million, which is an improvement from a net loss of $6.35 million last year. The improvement in net loss is attributable to a $0.8 million improvement in core operating results and a $2.3 million impairment charge recorded in the prior year period. 

Get the Full Report

Noble Capital Markets Research Report Thursday, May 29, 2025

Companies contained in today’s report:

MustGrow Biologics Corp. (MGROF)/MARKET PERFORM – A Pivotal Milestone; Reports 1Q25 Results
SKYX Platforms (SKYX)/OUTPERFORM – Joining the Russell
Superior Group of Companies (SGC)/OUTPERFORM – An Investment Opportunity In Keeping With Its Name

MustGrow Biologics Corp. (MGROF/$0.65)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
A Pivotal Milestone; Reports 1Q25 Results
Rating: MARKET PERFORM

Milestone Quarter. MustGrow’s 1Q25 was a pivotal milestone in the Company’s evolution, with the Company recording its first full quarter since the NexusBioAg acquisition at the end of 2024. MustGrow reported significant sales revenue for the first time, although higher expenses resulting from the acquisition drove a higher net loss.

1Q25 Results. Revenue totaled $3.78 million (all figures are Canadian $), compared to our $2.6 million estimate and zero in the year ago quarter. Gross margin was 14.3%, below our estimated 19.2%. MustGrow recorded a net loss of $1.6 million, or a loss of $0.03/sh, versus our estimate of a loss of $570,000, or a loss of $0.01/sh. In 1Q24, the Company reported a loss of $1.0 million, or a loss of $0.02/sh.

Get the Full Report

SKYX Platforms (SKYX/$1.32 | Price Target: $5)
Patrick McCann, CFA pmccann@noblefcm.com | (314) 724-6266
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Joining the Russell
Rating: OUTPERFORM

Joining the Russell Indices. FTSE Russell recently included the company in its preliminary additions to the Russell 2000 and broader Russell 3000 indices as part of its annual reconstitution. The inclusion will become effective at market open on June 27, offering a notable validation milestone for the company.

An important milestone. We believe this development could be a meaningful catalyst for SKYX. In our view, inclusion in the Russell indices will drive greater visibility among institutional investors and has the potential to increase average daily trading volume in the shares, supporting improved liquidity and broader shareholder participation.

Get the Full Report

Superior Group of Companies (SGC/$9.66 | Price Target: $16)
Michael Kupinski mkupinski@noblefcm.com | (561) 994-5734
Jacob Mutchler jmutchler@noblefcm.com |
An Investment Opportunity In Keeping With Its Name
Rating: OUTPERFORM

Initiating Coverage with Outperform rating and $16 price target. Our favorable rating is based on a company in sectors that should grow faster than the US economy, a seasoned, successful management team, a capable balance sheet positioned to support acquisition fueled growth, a history of return of capital to shareholders and a compelling stock valuation. 

Favorable industry trends. The company operates in three distinct sectors, healthcare apparel, branded products and call centers. Each segment has favorable, above-average organic growth characteristics, is profitable, and has compelling acquisition target opportunities for enhanced long-term revenue and cash flow growth.

Get the Full Report

Noble Capital Markets Research Report Wednesday, May 28, 2025

Companies contained in today’s report:

Graham (GHM)/OUTPERFORM – Awarded Large Follow-on Contract
Seanergy Maritime (SHIP)/OUTPERFORM – Better-than-Expected First Quarter Results

Graham (GHM/$40.77 | Price Target: $52)
Joe Gomes, CFA jgomes@noblefcm.com | 561-999-2262
Hans Baldau hbaldau@noblefcm.com |
Awarded Large Follow-on Contract
Rating: OUTPERFORM

New Award. Yesterday, Graham announced that its Barber-Nichols subsidiary was awarded a $136.5 million follow-on contract to support the U.S. Navy’s Virginia Class Submarine program. This new award strengthens Graham’s position as a critical supplier to the U.S. Navy’s undersea programs.

Details. The contract period of performance extends from April 2025 through February 2034. Graham recognized approximately $50 million in backlog from the contract during the fourth quarter of the fiscal year ended March 31, 2025 to procure long-lead-time materials. As a reminder, the backlog at the end of the fiscal third quarter totaled $384.7 million, just below a record high.

Get the Full Report

Seanergy Maritime (SHIP/$6.31 | Price Target: $9.25)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Hans Baldau hbaldau@noblefcm.com |
Better-than-Expected First Quarter Results
Rating: OUTPERFORM

First quarter results. Seanergy reported first-quarter net revenues of $24.2 million, slightly ahead of our estimate of $23.5 million, due to a higher-than-expected time charter equivalent (TCE) rate. Adjusted EBITDA and earnings per share (EPS) were $8.0 million and a loss of $0.27, respectively, compared to our estimates of $6.1 million and a loss of $0.38. The better-than-anticipated results are reflective of higher revenues as well as lower costs due to savings in general and administrative expenses.

Updating estimates. We are increasing our 2025 revenue estimates to $142.9 million from $142.5 million. Additionally, we are raising our adjusted EBITDA and EPS estimates to $70.5 million and $0.74, respectively, up from $68.1 million and $0.59. These revisions are reflective of management’s guidance of better-than-expected TCE rates and fewer dry-docking days, resulting in higher operating days and lower expenses.

Get the Full Report

Noble Capital Markets Research Report Tuesday, May 27, 2025

Companies contained in today’s report:

Comstock (LODE)/MARKET PERFORM – Comstock Achieves a Transformative Milestone

Comstock (LODE/$3.05)
Mark Reichman mreichman@noblefcm.com | (561) 999-2272
Comstock Achieves a Transformative Milestone
Rating: MARKET PERFORM

Annual general meeting. Comstock Inc. recently hosted its virtual annual general meeting. Shareholders voted to: 1) elect seven named nominees to the Board of Directors for the ensuing year or, if earlier, until their successors are duly elected and qualified, 2) to ratify the appointment of Assure CPA, LLC as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, and 3) to approve a non-binding advisory resolution for the compensation of named executive officers.

Separation of Comstock Fuels. Comstock Inc. officially separated and contributed the assets that formerly comprised Comstock’s fuels segment into Bioleum Corporation, a newly formed company that will operate independently with the objective of becoming a publicly traded company.

Get the Full Report

Just 24 hours after data showed job openings surging to their highest level since November 2024, the American labor market delivered a jarring reality check. Private sector employment unexpectedly contracted by 33,000 positions in June, according to ADP’s Wednesday report—marking the first monthly decline since March 2023 and painting a starkly different picture of employment dynamics.

The contradiction between Tuesday’s robust job openings data (7.76 million available positions) and Wednesday’s payroll contraction illustrates the complexity of today’s labor market, where demand for workers remains strong but actual hiring has stalled dramatically.

ADP’s report revealed a troubling disconnect between employer intentions and actions. While May data showed companies posting abundant job openings, June hiring patterns suggest businesses are increasingly reluctant to pull the trigger on new hires. The 33,000 job loss significantly missed economist expectations for 100,000 new positions, representing a stunning 133,000-job swing from forecasts.

“Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month,” explained Nela Richardson, ADP’s chief economist. This phenomenon—where companies maintain job postings but delay actual hiring decisions—reflects growing business uncertainty about economic conditions.

The May revision further underscored this trend, with private payroll gains reduced to just 29,000 from an initially reported 37,000, highlighting how even modest job growth has been weaker than initially perceived.

Service Sector Bears the Brunt

The June contraction was concentrated in service industries, with professional and business services shedding 56,000 positions and health and education losing 52,000 jobs. Financial services added to the decline with 14,000 fewer positions. These sectors, which typically drive white-collar employment growth, appear to be exercising extreme caution in their hiring strategies.

However, goods-producing industries provided some offset, adding 32,000 positions across manufacturing and mining operations. This divergence suggests that while consumer-facing and office-based businesses are pulling back, industrial sectors continue to see steady demand.

Geographically, the Midwest and West experienced the steepest declines, losing 24,000 and 20,000 jobs respectively, while the South managed modest growth of 13,000 positions. The Northeast saw minimal contraction of 3,000 roles.

The data revealed a striking pattern based on company size. Large employers with over 500 employees actually expanded payrolls by 30,000 positions, suggesting that well-capitalized companies continue to invest in talent acquisition. Conversely, small businesses with fewer than 20 employees accounted for 29,000 lost positions, indicating that smaller enterprises are bearing the brunt of economic uncertainty.

This divergence reflects different risk tolerances and financial capabilities, with smaller businesses typically more sensitive to economic headwinds and policy uncertainties.

Wage Growth Momentum Fades

Adding to concerns, annual wage growth decelerated for both job stayers and job switchers. Workers remaining in their positions saw pay increases of 4.4%, down from 4.5% in May, while those changing jobs experienced wage growth of 6.8%, declining from 7.0%. This moderation in wage pressures could provide some relief for inflation-conscious Federal Reserve officials but signals weakening worker bargaining power.

The stark contradiction between job openings and actual hiring creates a challenging environment for Federal Reserve policymakers already under pressure from the Trump administration to cut interest rates. While Tuesday’s job opening surge suggested labor market strength, Wednesday’s payroll contraction reinforces concerns about economic momentum.

Financial markets will closely watch Thursday’s official Bureau of Labor Statistics employment report, which economists expect to show 110,000 nonfarm payroll additions and unemployment rising to 4.3%. If the government data confirms ADP’s weak showing, it could significantly strengthen the case for monetary easing.

The divergent signals—strong job demand but weak hiring execution—suggest an economy in transition, where businesses remain optimistic enough to post openings but cautious enough to delay actual hiring decisions. This hesitancy may reflect concerns about tariff impacts, regulatory changes, or broader economic uncertainty.

For investors and policymakers alike, the labor market’s mixed messages underscore the importance of looking beyond headline numbers to understand the underlying dynamics driving employment trends in an increasingly complex economic environment.

AbbVie has announced a definitive agreement to acquire Capstan Therapeutics, a clinical-stage biotechnology company pioneering targeted in vivo cell engineering, in a deal valued at up to $2.1 billion. The acquisition includes Capstan’s lead asset, CPTX2309—an investigational therapy targeting B cell-mediated autoimmune diseases—as well as the company’s proprietary targeted lipid nanoparticle (tLNP) platform for RNA delivery.

This strategic move signals AbbVie’s growing commitment to reshaping the treatment landscape for autoimmune diseases. While AbbVie has long been a major player in immunology with blockbuster therapies like Humira and Rinvoq, the addition of Capstan’s in vivo CAR-T capabilities positions the company at the frontier of a new therapeutic modality.

CPTX2309 is an mRNA-based therapy that delivers an anti-CD19 chimeric antigen receptor (CAR) directly into CD8-expressing cytotoxic T cells via Capstan’s tLNP system. Unlike traditional ex vivo CAR-T therapies, which require harvesting and engineering a patient’s cells outside the body before reinfusion, CPTX2309 enables this transformation to happen in vivo. This significantly simplifies the treatment process by eliminating the need for lymphodepletion or complex manufacturing steps—making it potentially more scalable and accessible.

Targeting CD19, a well-validated marker expressed on B cells, CPTX2309 aims to deplete the autoreactive B cells responsible for driving autoimmune diseases such as lupus or multiple sclerosis. The goal is to eliminate the pathogenic immune cells and repopulate the system with naïve, healthy B cells—effectively resetting the immune system and halting disease progression.

AbbVie is not only acquiring a promising clinical candidate but also a platform technology with broad applications. Capstan’s proprietary CellSeeker™ tLNP platform can be adapted to deliver a variety of RNA payloads to specific cell types in vivo, opening possibilities far beyond autoimmune conditions. This could have future implications for oncology, infectious diseases, and more.

As part of the agreement, AbbVie will make a cash payment of up to $2.1 billion at closing, subject to customary regulatory and legal conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Act.

This acquisition adds to AbbVie’s expanding immunology pipeline and enhances its positioning in next-generation therapeutic development. By integrating Capstan’s cutting-edge technology, AbbVie aims to develop new approaches that go beyond treating symptoms and instead target the root causes of autoimmune disorders.

The transaction is expected to close later this year. Capstan was advised by Centerview Partners LLC as financial advisor and Cooley LLP as legal counsel. AbbVie did not disclose its legal or advisory team.

This deal reflects a growing industry trend of major pharmaceutical companies investing heavily in advanced RNA delivery platforms and in vivo cell therapies—technologies seen as essential to the next wave of personalized medicine. With this acquisition, AbbVie reaffirms its commitment to driving innovation that transforms the standard of care for patients worldwide.

Take a moment to take a look at more emerging growth biotechnology companies by taking a look at Noble Capital Markets’ analyst Robert LeBoyer’s coverage list.

Semiconductor stocks stumbled Friday after reports surfaced that the U.S. government is considering revoking waivers that currently allow major global chipmakers to use American technology in their Chinese operations.

According to The Wall Street Journal, Commerce Department official Jeffrey Kessler informed executives from Samsung Electronics, SK Hynix, and Taiwan Semiconductor Manufacturing Company (TSMC) earlier this week that the Biden administration is reviewing whether to terminate these exemptions. The waivers had enabled companies to export U.S. chipmaking tools and software to facilities in China, despite existing export controls.

The news triggered a wave of selling across the semiconductor sector. The VanEck Semiconductor ETF (SMH) dropped around 1%, while individual stocks including Nvidia, Qualcomm, and Marvell Technology fell roughly 1%. TSMC shares declined more than 2% as investors reacted to the potential disruption to its China-based operations.

The Commerce Department’s move signals a possible escalation in the ongoing tech tensions between Washington and Beijing. Although the two nations recently agreed on the framework of a second trade deal during meetings in London, the Biden administration has continued to tighten restrictions on advanced chip technology exports, citing national security concerns.

“These waivers were a key lifeline for chipmakers operating in China,” said Adam Kinley, an analyst at EastWest Securities. “If revoked, companies like TSMC and Samsung could face operational hurdles, reallocation costs, and potentially a sharp drop in revenue tied to China-based production.”

The semiconductor industry has already been navigating growing restrictions. In 2022 and 2023, the U.S. introduced sweeping controls limiting China’s access to advanced AI chips and tools required for high-end semiconductor fabrication. The latest efforts to close loopholes reflect Washington’s concern that Beijing could exploit foreign chip factories operating inside China to circumvent those controls.

The impact of these export curbs is already being felt. Nvidia, a leading AI chipmaker, disclosed last month that U.S. government restrictions on its China-bound H20 chips contributed to an estimated $8 billion hit in sales. CEO Jensen Huang described the China market—once worth $50 billion to U.S. chip companies—as “effectively closed.”

The potential rollback of waivers could further strain U.S.-China trade relations, particularly as China has denounced these restrictions as discriminatory. While the current policy discussions are ongoing and no final decision has been made, the possibility of more sweeping limits has introduced fresh volatility into the sector.

Investors and chipmakers alike will be watching closely for any formal announcements in the coming weeks. A reversal of the waivers would force affected companies to reevaluate supply chains, consider shifting manufacturing operations out of China, and potentially delay production schedules.

In the near term, analysts expect heightened market sensitivity to any government signals or diplomatic developments related to U.S.-China tech policy. As Washington balances national security priorities with global economic interests, the semiconductor industry finds itself once again at the center of geopolitical risk.

In a major step forward for the future of mRNA-based medicine, BioNTech SE has announced it will acquire fellow German biotech firm CureVac N.V. in an all-stock deal valued at approximately $1.25 billion. The transaction is set to bolster BioNTech’s capabilities in cancer immunotherapy and mRNA research, positioning the company for deeper innovation and broader commercialization in oncology.

Under the terms of the agreement, CureVac shareholders will receive approximately $5.46 in BioNTech American Depositary Shares (ADSs) for each CureVac share—representing a 55% premium over CureVac’s three-month average trading price. The exchange ratio will be adjusted depending on the 10-day average trading price of BioNTech stock leading up to the deal’s closure. Upon completion, CureVac shareholders are expected to own between 4% and 6% of BioNTech’s outstanding shares.

Both companies are pioneers in mRNA-based technologies, with BioNTech gaining international prominence for its COVID-19 vaccine co-developed with Pfizer. CureVac has long focused on developing mRNA therapeutics for cancer and infectious diseases. The deal unites two complementary platforms, merging BioNTech’s commercial success and oncology pipeline with CureVac’s expertise in mRNA design and lipid nanoparticle (LNP) delivery systems.

“This transaction is another building block in BioNTech’s oncology strategy and an investment in the future of cancer medicine,” said Prof. Ugur Sahin, CEO and Co-Founder of BioNTech. “By combining our strengths, we aim to accelerate the development of innovative and transformative cancer treatments that could become new standards of care.”

CureVac CEO Dr. Alexander Zehnder echoed Sahin’s sentiment, describing the acquisition as a shared mission rather than just a financial deal. “For more than 20 years, both companies have worked toward unlocking the potential of mRNA. This union represents a powerful convergence of technologies, cultures, and visions to push the boundaries of what’s possible in medicine,” Zehnder said.

The acquisition will integrate CureVac’s advanced R&D and manufacturing site in Tübingen into BioNTech’s broader operations. CureVac will become a wholly owned subsidiary of BioNTech, and a full corporate reorganization will follow the completion of the exchange offer, expected later this year.

The deal already has substantial shareholder backing. CureVac’s largest investor, dievini Hopp BioTech, and its affiliates—which collectively hold over 36% of CureVac shares—have agreed to support the transaction. Including other key stakeholders and the German government’s investment arm, BioNTech expects support from shareholders holding more than 50% of CureVac’s shares, positioning the company well to meet the 80% acceptance threshold required to finalize the transaction.

The boards of both companies have unanimously approved the deal, which now awaits regulatory approval and final shareholder votes. Legal and financial advisors for the deal include Covington & Burling LLP and PJT Partners for BioNTech, and Goldman Sachs and Skadden for CureVac.

This acquisition cements BioNTech’s strategy to lead the next generation of cancer therapies, leveraging the full power of mRNA science in the fight against some of the world’s most challenging diseases.

Take a moment to take a look at other emerging growth biotech companies by taking a look at Noble Capital Markets Research Analyst Robert Leboyer’s coverage list.

Key Points: – Quantum computing stocks surged after Nvidia’s CEO said the field is nearing an “inflection point.” – IBM’s announcement of a fault-tolerant quantum computer by 2029 marks a breakthrough toward real-world applications. – Big Tech and investors alike are ramping up bets on quantum as its commercial potential begins to materialize.

Shares of quantum computing companies soared midweek following a wave of renewed optimism about the sector’s near-term potential. The rally was sparked by remarks from Nvidia CEO Jensen Huang, who highlighted the accelerating pace of progress in quantum technology during the company’s developer conference in Paris.

Huang told attendees that quantum computing is approaching a pivotal stage in its development — a shift from theoretical promise to tangible application. His statements mark a notable departure from his more conservative estimates earlier this year, when he suggested commercially viable quantum machines could be decades away. This change in tone sent investor sentiment surging.

As a result, several companies in the space saw their stock prices jump significantly. Quantum Computing Inc. gained over 30% in early trading Wednesday, while Rigetti Computing and IonQ also posted strong single- and double-digit gains. The moves stand out against a largely flat broader market, reflecting growing confidence in the industry’s progress and future revenue potential.

The renewed excitement comes just one day after IBM revealed plans to launch the world’s first large-scale quantum computer designed to run without the common errors that have plagued existing systems. That machine is expected to debut by 2029, representing what analysts view as a meaningful advance toward practical, scalable quantum computing.

Unlike traditional computers, which process information in binary form, quantum computers harness the principles of quantum mechanics to perform calculations at exponentially faster speeds. Their unique architecture holds the potential to revolutionize fields that require complex computation, such as cryptography, materials science, drug discovery, and optimization problems in logistics.

However, the path to that reality has been hindered by a major obstacle: quantum systems are notoriously sensitive to external interference, often producing inaccurate results. IBM’s announcement, alongside accelerated efforts from major players like Google, Amazon, and Microsoft, signals a growing industry-wide push to solve these reliability challenges.

Nvidia’s increasing involvement in the sector further underscores the growing convergence between quantum and classical computing. In March, the company hosted its first-ever “Quantum Day” and announced plans to establish a quantum research hub in Boston. The move reflects Nvidia’s strategy to remain at the forefront of next-generation computing platforms as it expands beyond AI chips into quantum-ready infrastructure.

While fully fault-tolerant quantum systems may still be years away, the latest developments suggest progress is unfolding faster than many previously expected. If the momentum continues, quantum computing could become one of the most disruptive technologies of the next decade.

Key Points: – CPI and PPI inflation reports for May are due this week, with modest increases expected but upside risks from tariffs. – Treasury auctions of 10- and 30-year bonds will test investor demand amid rising deficits and higher yields. – The results may influence Federal Reserve policy and market volatility, especially if inflation surprises to the upside.

Investors are bracing for a potentially volatile week as key inflation reports and large government bond auctions test the strength of the U.S. fixed income market. With concerns rising around growing fiscal deficits, tariffs, and monetary policy uncertainty, both data and demand will be under a microscope.

The Bureau of Labor Statistics is set to release two important indicators: the Consumer Price Index (CPI) for May on Wednesday, followed by the Producer Price Index (PPI) on Thursday. These readings come at a delicate time for markets already on edge over the potential long-term impact of President Trump’s recent tariffs and record government spending.

Economists forecast modest increases, with CPI expected to rise 0.2% month-over-month and 2.4% year-over-year. The core CPI, which excludes food and energy, is projected to climb 0.3% from April and 2.9% annually. Producer prices, which declined in April, are expected to bounce back slightly, with consensus pointing to a 0.2% monthly gain in headline PPI and 0.3% in the core reading.

However, any upward surprise in the data could disrupt fragile investor sentiment, especially as rising inflationary pressures threaten to delay future interest rate cuts by the Federal Reserve. Traders will be closely analyzing the data for signs of whether the recent tariffs are starting to flow through to consumer and producer prices.

Compounding the pressure, the U.S. Treasury will hold two major auctions this week: $39 billion in 10-year notes on Wednesday and $22 billion in 30-year bonds on Thursday. These long-duration securities will act as a litmus test for investor demand at a time when U.S. debt levels are drawing increased scrutiny from both markets and policymakers.

Key metrics from the auctions — such as the bid-to-cover ratio, the level of indirect bids, and the yield “tail” — will offer insight into how much appetite exists for U.S. debt amid rising deficits. Yields have already surged in recent weeks as investors demand greater compensation for holding Treasurys amid growing fiscal and geopolitical risks.

While the market remains relatively stable for now, analysts warn that a sudden jump in yields — driven either by weak auction demand or unexpected inflationary pressure — could send ripple effects across equities, credit markets, and consumer borrowing costs.

The bond market has been adjusting ever since the Fed’s rate cut last September, with yields taking another leg higher following Trump’s early April tariff announcement. The impact of these policies may be further amplified if inflation data begins trending upward over the coming months.

Even amid concerns, some analysts remain cautiously optimistic. Strong relative yields on U.S. Treasurys compared to global peers and signs of a cooling economy may continue to attract foreign and institutional investors seeking safety and steady returns.

Still, with inflation readings, bond supply, and fiscal policy all converging this week, investors are likely to remain on high alert. The outcomes of these events could shape not only the direction of yields but also the Federal Reserve’s monetary roadmap heading into the second half of 2025.